New vaccine aims to boost immune system against advanced breast cancer

NCT ID NCT07112053

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a vaccine called STEMVAC in people with hormone receptor-positive, HER2-negative breast cancer that has spread. The vaccine is designed to help the immune system attack cancer cells. Participants will receive STEMVAC along with their usual hormone therapy, a targeted drug, or chemotherapy. The goal is to see if the combination is safe and helps control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer Her2-receptor negative breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANATOMIC STAGE IV BREAST CANCER AJCC V8 METASTATIC HER2-NEGATIVE BREAST CARCINOMA METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.